Observational studyCancer2025
The BEV1L study: Do real-world outcomes associated with the addition of bevacizumab to first-line chemotherapy in patients with ovarian cancer reinforce clinical trial findings?
Observational study in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Metformin-A Type 2 Diabetes Mellitus Drug-And Ovarian Cancer: Anticancer Mechanisms and Therapeutic Implications.Biomolecules · 2026Review
- Article
- Survival outcomes of low-dose and high-dose bevacizumab front-line maintenance in advanced high-grade serous ovarian cancer: a propensity score-matched real-world study.Frontiers in oncology · 2026Article
- Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundIn clinical trials, adding bevacizumab to first-line (1L) chemotherapy for Stage III/IV epithelial ovarian cancer significantly improved progression-free survival but not overall survival (OS). Post hoc analyses suggested potentially greater benefit from the addition of bevacizumab in patients with high-risk prognostic factors.
methodsEligible patients in this nationwide, deidentified, electronic health record-derived database study had Stage III/IV epithelial ovarian cancer and initiated 1L chemotherapy ± bevacizumab (January 1, 2017-May 31, 2023). High-risk prognostic factors were defined as having Stage IV disease or Stage III disease with either visible residual disease or no documentation of surgery. Median real-world time to next treatment and real-world OS, indexed to 1L initiation, were estimated by Kaplan-Meier methods. Cox proportional hazards models assessed associations between patient characteristics and 1L treatment received, with each real-world outcome.
resultsAmong 1752 patients, median (interquartile range) age was 68 (60-75) years; median (interquartile range) follow-up time was 18.5 (8.0-36.6) months. Among patients with high-risk prognostic factors, median (95% CI) real-world time to next treatment was significantly longer with 1L chemotherapy plus bevacizumab (13.6 [12.7-15.9] months) than chemotherapy alone (11.7 [10.6-12.6] months; p = .032). There was a trend toward longer median (95% CI) real-world OS with 1L chemotherapy plus bevacizumab (31.1 [27.7-37.5] months) versus chemotherapy (27.4 [25.1-31.2] months; p = .052). For patients without high-risk prognostic factors, real-world outcomes did not differ with the addition of bevacizumab.
conclusionsThese real-world results support clinical trial data suggesting the benefit of adding bevacizumab to 1L chemotherapy may be limited to patients with high-risk prognostic factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.